可溶性尿激酶纤溶酶原激活物受体与CKD患者心血管事件的前瞻性队列研究
在德国慢性肾脏病(GCKD)队列4994例CKD患者中,中位suPAR为1771 pg/ml,随访6.5年期间发生573例死亡(含190例心血管死亡)和683例主要心血管事件(MACE)。多变量分析显示,suPAR(log2)与全因死亡(HR 1.36)、心血管死亡(HR 1.27)和MACE(HR 1.13)相关,且该关联不随糖尿病状态、基线eGFR、UACR或甲状旁腺激素水平而不同。
要点
- suPAR水平与CKD患者全因死亡、心血管死亡及MACE独立相关。
- suPAR与结局的关联不因糖尿病、eGFR、UACR或PTH水平而改变。
- 中介分析中suPAR对全因死亡的直接效应占77%,经eGFR介导占23%。
核心结论
- 在大型CKD队列中,suPAR水平与死亡和心血管结局相关,且独立于肾功能指标,符合其在动脉粥样硬化发病中的独立作用。
研究设计与样本
- 前瞻性队列研究,纳入德国慢性肾脏病(GCKD)队列4994例参与者,平均年龄60岁,60%为男性,36%有糖尿病,平均eGFR 49 ml/min per 1.73 m2(SD 18)。
主要发现
- 中位suPAR水平为1771 pg/ml(IQR 1447-2254 pg/ml),suPAR水平与年龄、eGFR、UACR和甲状旁腺激素水平呈正独立相关。
- 随访6.5年期间共发生573例死亡(包括190例心血管死亡)和683例MACE事件。
- 多变量分析中,suPAR(log2)与全因死亡相关(HR 1.36,95% CI 1.21-1.53)。
- suPAR(log2)与心血管死亡相关(HR 1.27,95% CI 1.03-1.57)。
- suPAR(log2)与MACE相关(HR 1.13,95% CI 1.00-1.28),且未发现该关联随糖尿病状态、基线eGFR、UACR或甲状旁腺激素水平而不同。
临床怎么用
- 在CKD患者中,suPAR水平与全因死亡、心血管死亡和MACE独立相关,且不依赖于eGFR、UACR等肾功能指标。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Soluble urokinase plasminogen activation receptor (suPAR) is an immune-derived pathogenic factor for kidney and atherosclerotic disease. Whether the association between suPAR and cardiovascular (CV) outcomes is dependent on the severity of underlying kidney disease is unclear. METHODS: We measured serum suPAR levels in 4994 participants (mean age 60 years; 60% men; 36% with diabetes mellitus; mean estimated glomerular filtration rate (eGFR) 49 ml/min per 1.73 m2, SD 18) of the German Chronic Kidney Disease (GCKD) cohort and examined its association with all-cause death, CV death, and major CV events (MACE) across the range of eGFR and urine albumin-to-creatinine ratio (UACR). RESULTS: The median suPAR level was 1771 pg/ml (interquartile range [IQR] 1447-2254 pg/ml). SuPAR levels were positively and independently correlated with age, eGFR, UACR, and parathyroid hormone levels. There were 573 deaths, including 190 CV deaths and 683 MACE events at a follow-up time of 6.5 years. In multivariable analyses, suPAR levels (log2) were associated with all-cause death (hazard ratio [HR] 1.36, 95% confidence interval [CI] 1.21-1.53), CV death (HR 1.27, 95% CI 1.03-1.57), and MACE (HR 1.13, 95% CI 1.00-1.28), and were not found to differ according to diabetes mellitus status, baseline eGFR, UACR, or parathyroid hormone levels. In mediation analysis, suPAR's direct effect on all-cause death, CV death, and MACE accounted for 77%, 67%, and 60% of the total effect, respectively; whereas the effect mediated through eGFR accounted for 23%, 34%, and 40%, respectively. CONCLUSION: In a large cohort of individuals with chronic kidney disease (CKD), suPAR levels were associated with mortality and CV outcomes independently of indices of kidney function, consistent with its independent role in the pathogenesis of atherosclerosis.
引用
- Sommerer C, Müller-Krebs S, Nadal J, et al. Prospective Cohort Study of Soluble Urokinase Plasminogen Activation Receptor and Cardiovascular Events in Patients With CKD. Kidney Int Rep. 2023. PMID: 38025216. doi:10.1016/j.ekir.2023.08.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。